---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-26-000004"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T04:54:44.937638+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q4 revenue $16.6B (+10%); FY2025 adj EPS $10.00; guides FY2026 adj EPS $14.37-$14.57

## Summary
- FY2025 revenue $61.160B (+8.6% reported); GAAP diluted EPS $2.36; adjusted diluted EPS $10.00 (-1.2% YoY).
- Q4 revenue $16.618B (+10% reported); GAAP EPS $1.02; adjusted EPS $2.71; includes $0.71 IPR&D hit.
- Immunology portfolio grew 14% in FY2025; Skyrizi $17.562B, Rinvoq $8.304B; Humira fell to $4.540B.
- FY2026 adjusted EPS guidance $14.37-$14.57, excluding future IPR&D and milestones expense.
- Announced voluntary pricing agreement with Trump admin; $100B U.S. R&D/capex over 10 years.

## SEC filing metadata
- accession: 0001551152-26-000004
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/0001551152-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/abbv-20260204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-26-000004
- JSON: https://secwatch.observer/filing/0001551152-26-000004.json
- Plain text: https://secwatch.observer/filing/0001551152-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.